Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB | Zendy

Anushka Naidoo | Zendy; Maxwell Chirehwa | Zendy; Helen McIlleron | Zendy; Kogieleum Naidoo | Zendy; Sabiha Y. Essack | Zendy; hlanhla YendeZuma | Zendy; Eddy Kimba-Phongi | Zendy; John Adamson | Zendy; Katya Govender | Zendy; Nesri Padayatchi | Zendy; Paolo Denti | Zendy

Open Access

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB

Author(s) -

Anushka Naidoo,

Maxwell Chirehwa,

Helen McIlleron,

Kogieleum Naidoo,

Sabiha Y. Essack,

hlanhla YendeZuma,

Eddy Kimba-Phongi,

John Adamson,

Katya Govender,

Nesri Padayatchi,

Paolo Denti

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx004

Subject(s) - moxifloxacin , rifampicin , efavirenz , pharmacokinetics , medicine , pyrazinamide , pharmacology , isoniazid , regimen , antibacterial agent , antibiotics , tuberculosis , human immunodeficiency virus (hiv) , chemistry , antiretroviral therapy , viral load , immunology , biochemistry , pathology

We compared the pharmacokinetics of moxifloxacin during rifampicin co-treatment or when dosed alone in African patients with drug-susceptible recurrent TB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research